Last reviewed 2026-05-23 · How we verify

RIMAZOLIUM

Phase 2 active Small molecule ✓ Verified May 2026

RIMAZOLIUM is a rimazolium drug. It is currently in Phase 2 development.

Rimazolium is thought to work by interacting with a specific cellular target, but the exact nature of this interaction is not well understood.

Rimazolium is a small molecule. It is also known by its synonyms, Rimazolium Cation and Rimazolium Ion.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RIMAZOLIUM
Drug class	rimazolium
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells as locks on a door. Rimazolium is like a key that fits into one of these locks, but we don't know which lock it is or how it works once it's inside. This interaction can affect how cells behave and respond to signals.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RIMAZOLIUM CI brief — competitive landscape report
RIMAZOLIUM updates RSS · CI watch RSS

Frequently asked questions about RIMAZOLIUM

What is RIMAZOLIUM?

RIMAZOLIUM is a rimazolium drug.

How does RIMAZOLIUM work?

Rimazolium is thought to work by interacting with a specific cellular target, but the exact nature of this interaction is not well understood.

What drug class is RIMAZOLIUM in?

RIMAZOLIUM belongs to the rimazolium class. See all rimazolium drugs at /class/rimazolium.

What development phase is RIMAZOLIUM in?

RIMAZOLIUM is in Phase 2.

Drug class: All rimazolium drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing